Pancreatic Cancer

Data reported from study combining TNFerade with chemo and radiation

Published in Cancer Weekly, June 24th, 2003

GenVec, Inc., (GNVC) announced preliminary data from the dose escalation portion of a phase II study using TNFerade in combination with chemotherapy and radiation in patients with locally advanced, inoperable pancreatic cancer.

The results, presented in a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, indicated that TNFerade, when used in combination with standard chemotherapy and radiation, was well-tolerated at the two dose levels evaluated to date.

Local control or stabilization of the treated tumors was also seen in 11 of the 17 evaluable patients (65%) as reported by an independent...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry